Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Revenue (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Revenue for 16 consecutive years, with $521000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue changed N/A to $521000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.8 million, a 60.32% decrease, with the full-year FY2024 number at $9.8 million, down 6.45% from a year prior.
  • Revenue was $521000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $2.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $4.4 million in Q4 2021 to a low of $521000.0 in Q3 2025.
  • A 5-year average of $2.7 million and a median of $2.8 million in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 134.32% in 2021, then crashed 51.12% in 2023.
  • NovaBay Pharmaceuticals' Revenue stood at $4.4 million in 2021, then dropped by 17.65% to $3.6 million in 2022, then tumbled by 42.33% to $2.1 million in 2023, then rose by 9.9% to $2.3 million in 2024, then crashed by 77.44% to $521000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Revenue are $521000.0 (Q3 2025), $2.3 million (Q4 2024), and $3.2 million (Q2 2024).